Public Health Implications of Rapid Hepatitis C Screening with an Oral Swab for Community-based Organizations Serving High-risk Populations

Overview

Journal Am J Public Health

Specialty Public Health

Date 2011 Sep 24

PMID 21940910

Citations 34

Authors

Ann Drobnik

Caroline Judd

David Banach

Joseph Egger

Kevin Konty

Eric Rude

Affiliations

Soon will be listed here.

Abstract

Objectives: Between April and September of 2009 we evaluated the accuracy of the OraQuick HCV rapid antibody test and assessed its feasibility for use by community-based organizations (CBOs) serving populations at high risk for HCV in New York City.

Methods: We compared the results of screening by OraQuick (oral swab) and enzyme immunoassay (EIA; blood draw). We performed ribonucleic acid polymerase chain reaction testing for discordant results. We also assessed research staff perceptions through a survey and focus group.

Results: Overall, 97.5% of OraQuick and EIA results matched. Testing of discordant samples indicated that the rapid test was more likely than the EIA to provide a correct diagnosis. Research staff preferred the rapid test and identified challenges that would be overcome with its use. CBOs could benefit from increased testing capacity, and clients might benefit from more rapid access to education, counseling, and referrals.

Conclusions: OraQuick's accuracy is comparable to the EIA. The oral swab rapid test could help HCV screening programs reach individuals unaware of their status and expand testing into nonclinical settings such as mobile units.

Citing Articles

Detection of Epstein‒Barr virus DNA methylation as tumor markers of nasopharyngeal carcinoma patients in saliva, oropharyngeal swab, oral swab, and mouthwash.

Zheng X, Li X, Tang C, Zhang Y, Zhou T, Yang X MedComm (2020). 2024; 5(9):e673.

PMID: 39161799 PMC: 11331033. DOI: 10.1002/mco2.673.

Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.

Conway A, Read P, Gilliver R, McNaughton T, Valerio H, Cunningham E Viruses. 2022; 14(11).

PMID: 36366561 PMC: 9696805. DOI: 10.3390/v14112463.

Evaluation of saliva self-collection devices for SARS-CoV-2 diagnostics.

Allicock O, Petrone M, Yolda-Carr D, Breban M, Walsh H, Watkins A BMC Infect Dis. 2022; 22(1):284.

PMID: 35337266 PMC: 8953967. DOI: 10.1186/s12879-022-07285-7.

Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia.

Uuskula A, Talu A, Rannap J, Barnes D, Des Jarlais D Harm Reduct J. 2021; 18(1):39.

PMID: 33794927 PMC: 8015736. DOI: 10.1186/s12954-021-00485-5.

Oral swab testing by Xpert® MTB/RIF Ultra for mass tuberculosis screening in prisons.

Lima F, Santos A, Oliveira R, Silva C, Goncalves C, Andrews J J Clin Tuberc Other Mycobact Dis. 2020; 19:100148.

PMID: 32099908 PMC: 7031315. DOI: 10.1016/j.jctube.2020.100148.

References

Shiffman M, Suter F, Bacon B, Nelson D, Harley H, Sola R . Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357(2):124-34. DOI: 10.1056/NEJMoa066403. View

Thuluvath P, Guidinger M, Fung J, Johnson L, Rayhill S, Pelletier S . Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010; 10(4 Pt 2):1003-19. DOI: 10.1111/j.1600-6143.2010.03037.x. View

Cohen M, Grey D, Cook J, Anastos K, Seaberg E, Augenbraun M . Awareness of hepatitis C infection among women with and at risk for HIV. J Gen Intern Med. 2007; 22(12):1689-94. PMC: 2219830. DOI: 10.1007/s11606-007-0395-x. View

Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F . Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2007; 121(6):710-9. PMC: 1781913. DOI: 10.1177/003335490612100611. View

. Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 1998-1999 (as of 25 November 1999). Wkly Epidemiol Rec. 2000; 74(49):421-4. View

Sullivan P, Lansky A, Drake A . Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. J Acquir Immune Defic Syndr. 2004; 35(5):511-8. DOI: 10.1097/00126334-200404150-00009. View

Bornschlegel K, Berger M, Garg R, Punsalang A, McKinney C, Gwynn R . Prevalence of hepatitis C infection in New York City, 2004. J Urban Health. 2009; 86(6):909-17. PMC: 2791819. DOI: 10.1007/s11524-009-9396-x. View

McHutchison J, Lawitz E, Shiffman M, Muir A, Galler G, McCone J . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6):580-93. DOI: 10.1056/NEJMoa0808010. View

. Recommended adult immunization schedule: United States, 2010. Ann Intern Med. 2010; 152(1):36-9. DOI: 10.7326/0003-4819-152-1-201001050-00008. View

10.

McGinn T, OConnor-Moore N, Alfandre D, Gardenier D, Wisnivesky J . Validation of a hepatitis C screening tool in primary care. Arch Intern Med. 2008; 168(18):2009-13. DOI: 10.1001/archinte.168.18.2009. View

11.

Dhopesh V, Taylor K, Burke W . Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000; 26(4):703-7. DOI: 10.1081/ada-100101903. View

12.

Antonio-Gaddy M, Richardson-Moore A, Burstein G, Newman D, Branson B, Birkhead G . Rapid HIV antibody testing in the New York State Anonymous HIV Counseling and Testing Program: experience from the field. J Acquir Immune Defic Syndr. 2006; 43(4):446-50. DOI: 10.1097/01.qai.0000243055.65698.51. View

13.

Armstrong G, Wasley A, Simard E, McQuillan G, Kuhnert W, Alter M . The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10):705-14. DOI: 10.7326/0003-4819-144-10-200605160-00004. View

14.

Liang T, Erbelding E, Jacob C, Wicker H, Christmyer C, Brunson S . Rapid HIV testing of clients of a mobile STD/HIV clinic. AIDS Patient Care STDS. 2005; 19(4):253-7. DOI: 10.1089/apc.2005.19.253. View

15.

Lee S, Kardos K, Schiff E, Berne C, Mounzer K, Banks A . Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2010; 172(1-2):27-31. DOI: 10.1016/j.jviromet.2010.12.009. View

16.

Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S . Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2007; 15(4):250-4. DOI: 10.1111/j.1365-2893.2007.00937.x. View

17.

Lee S, Yearwood G, Guillon G, Kurtz L, Fischl M, Friel T . Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol. 2010; 48(1):15-7. DOI: 10.1016/j.jcv.2010.02.018. View